美国 · SEC FORM 4
Immix Biopharma, Inc.
IMMX · Nasdaq · CIK 0001873835 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
7 同一窗口内观察到的 Form 4 交易行
0 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-12-10 · Rachman Ilya M.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 10,390,288
- 上期报告
- 9,621,660
- 日均成交量
- 2,032,334
- 回补天数
- 5.1
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-12-10 | Rachman Ilya M | 买入 (P) | Common Stock | 746 | USD 6.67 | USD 4,976 | SEC 申报 ↗ |
| 2025-12-10 | Morris Gabriel S | 买入 (P) | Common Stock | 770 | USD 6.58 | USD 5,067 | SEC 申报 ↗ |
| 2025-09-17 | Rachman Ilya M | 买入 (P) | Common Stock | 2,500 | USD 2.02 | USD 5,050 | SEC 申报 ↗ |
| 2025-09-16 | Morris Gabriel S | 买入 (P) | Common Stock | 2,600 | USD 1.97 | USD 5,122 | SEC 申报 ↗ |
| 2025-06-18 | Rachman Ilya M | 买入 (P) | Common Stock | 2,178 | USD 2.30 | USD 5,009 | SEC 申报 ↗ |
| 2025-06-18 | Morris Gabriel S | 买入 (P) | Common Stock | 2,225 | USD 2.28 | USD 5,073 | SEC 申报 ↗ |
| 2024-12-23 | Hsu Jason | 买入 (P) | Common Stock | 40,000 | USD 2.19 | USD 87,600 | SEC 申报 ↗ |
| 2024-12-20 | Hsu Jason | 买入 (P) | Common Stock | 7,700 | USD 2.17 | USD 16,709 | SEC 申报 ↗ |
| 2024-08-22 | Hsu Jason | 买入 (P) | Common Stock | 8,100 | USD 2.25 | USD 18,225 | SEC 申报 ↗ |
| 2024-08-21 | Hsu Jason | 买入 (P) | Common Stock | 15,000 | USD 2.23 | USD 33,450 | SEC 申报 ↗ |
| 2024-08-16 | Ng Carey | 买入 (P) | Common Stock | 10,000 | USD 1.86 | USD 18,600 | SEC 申报 ↗ |
| 2024-07-24 | Hsu Jason | 买入 (P) | Common Stock | 6,000 | USD 2.15 | USD 12,900 | SEC 申报 ↗ |
| 2024-07-18 | Hsu Jason | 买入 (P) | Common Stock | 3,200 | USD 2.07 | USD 6,624 | SEC 申报 ↗ |
| 2024-06-07 | Rachman Ilya M | 买入 (P) | Common Stock | 2,600 | USD 2.13 | USD 5,538 | SEC 申报 ↗ |
| 2024-06-07 | Morris Gabriel S | 买入 (P) | Common Stock | 2,500 | USD 2.12 | USD 5,300 | SEC 申报 ↗ |
Form 4 申报证据
10 transaction lines in the latest 365-day window; 66 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Ng Carey | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Marquet Magda | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Hsu Jason | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (10 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-05-22 | Ng Carey | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Marquet Magda | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Hsu Jason | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Chudnovsky Yekaterina | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | CHANG NANCY T | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | BUCHAN JANE | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-22 | Adams Helen C. | 奖励／授予 (A) | Common Stock | 6,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-10 | Rachman Ilya M | 买入 (P) | Common Stock | 746 | USD 6.67 | USD 4,976 | SEC 申报 ↗ |
| 2025-12-10 | Morris Gabriel S | 买入 (P) | Common Stock | 770 | USD 6.58 | USD 5,067 | SEC 申报 ↗ |
| 2025-12-08 | Morris Gabriel S | X (X) | Common Stock | 156,000 | USD 0.80 | USD 124,800 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IMMX |
| CIK | 0001873835 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 66 transaction lines from 2021-12-17 to 2026-05-22 42 P purchase lines · 2 S sale lines · 22 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.